Kif14: A clinically relevant kinesin and potential target for cancer therapy

Brigitte L. Thériault, Timothy W. Corson

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Scopus citations

Abstract

Kinesin family member 14 (KIF14) is an atypical N-3 kinesin identified as a potential oncogene in the prototypic genetic cancer retinoblastoma. KIF14 is crucial for the last phases of cytokinesis, where it interacts with protein regulating cytokinesis 1 (PRC1), citron kinase (CIT) and supervillin to mediate formation of the cleavage furrow. However its importance in cancer is perhaps better characterized than its cell biology, and has generated much interest in this kinesin as a potential prognostic marker and exciting therapeutic target. Located on chromosome 1q32.1, a common region of gain in many cancers, KIF14 demonstrates genomic gain and overexpression in multiple neoplasms. KIF14 expression is tumor-specific, and in breast, lung, ovarian, liver, and brain cancers expression correlates with stage, aggressiveness and poor patient outcomes. In cancer cells, KIF14 interacts with tumorigenic signaling pathways that promote cellular behaviors such as adhesion, invasion and chemotherapeutic resistance, with the end result of promoting tumor progression. Here we discuss the mounting evidence pointing to KIF14 as a prognostic marker and oncogenic stimulus in multiple cancers, as well as the additional evidence required for validation of KIF14 as a potential drug target.

Original languageEnglish (US)
Title of host publicationKinesins and Cancer
PublisherSense Publishers
Pages149-170
Number of pages22
ISBN (Electronic)9789401797320
ISBN (Print)9789401797313
DOIs
StatePublished - Jan 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)

Cite this